JNJ NYSE Week ended 24 Jul 2026

Weekly Investor Report

Johnson & Johnson · Healthcare · Drug Manufacturers - General

Open interactive chart View report data Download investor PDF
Latest close 263.4 USD
4.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 12.2% above the Trend Line and sits at 94.5% of its 52-week range. The latest completed week returned 4.1%, after a 3.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 48/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high; earnings are due in 76d.

Setup score 71 out of 100
Latest Close 263.4 USD 24 Jul 2026
1W Return 4.1% latest completed week
4W Return 3.4% short-term follow-through
12W Return 16.6% quarterly tape
Trend Breadth 100.0% 52 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 69-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 4 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.1% Latest completed week; four-week move 3.4%. Indicator stack 100/95 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 48/100 conviction; expected move 2.2%. News sentiment 54/100 36 relevant articles in the latest sentiment read. Event risk 76d Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 12.2% above the Trend Line and sits at 94.5% of its 52-week range. The latest completed week returned 4.1%, after a 3.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6412-week average 0.59

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.64Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 3.4% over four weeks, 16.6% over 12 weeks, and 60.4% over one year. The current trend has remained active for 69 consecutive weeks.

Performance by holding period

1W4.1%
4W3.4%
12W16.6%
26W21.0%
52W60.4%
Active trend streak69 weeks
Active weeks in one year52
Trend breadth100.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.63Latest activity-pressure read.
Pressure change414.5%Four-week change in activity pressure.
Leadership14.25Latest relative-leadership reading.
RS change-2.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 97% Model confidence 97%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value9/100Relative valuation strength. Underlying universe rank 92; rank 1 is best.
Quality91/100Profitability and accounting quality. Underlying universe rank 10; rank 1 is best.
Momentum89/100Medium-term price momentum. Underlying universe rank 12; rank 1 is best.
Growth31/100Revenue and earnings growth. Underlying universe rank 70; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
30.2x
Price divided by trailing earnings.
Price / sales
6.5x
Market value relative to trailing revenue.
EV / EBITDA
20.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
4.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
70.5%
Gross profit retained from each unit of revenue.
Operating margin
26.7%
Operating profit retained from revenue.
Free-cash-flow margin
29.3%
Free cash flow generated from revenue.
Return on invested capital
19.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.1%
Latest one-year revenue growth.
EPS growth
-7.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-3.2%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
2.0%
Cash dividends relative to market value.
Buyback yield
1.3%
Net share repurchases relative to market value.
Shareholder yield
3.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.9x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

JNJ shows bullish options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 2.2%, and Sharemaestro trend signal active.

Conviction48/100
Expected move2.2%
Put/call volume0.25
Pressure63
Speculation43
Volatility29
Trend agreement34
Open options detail
Insider activity13 / 7

13 acquisitions and 7 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 36 relevant articles.

10 positive · 23 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings76dNext report is scheduled for 13 Oct 2026; event risk rises as the date approaches.
Options expected move2.2%Nearest-chain priced movement where available.
52-week drawdown-2.2%Distance below the 52-week high.
13-week volatility4.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+11.5%Week of 26 Jun.
Worst week-5.2%Week of 19 Jun.
Latest week+4.1%Week of 24 Jul.

Shape of recent returns

Strong gains3
Modest gains11
Flat weeks0
Modest losses11
Sharp losses1
Recent vol4.2%13-week weekly-return volatility.
Base vol3.1%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew3.1% / -1.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape74/100

Trend, activity pressure, participation, and risk combine to a 74/100 tape read.

 Indicator analysis61/100

Latest 12-week confirmation: trend 12/12, activity pressure 4/12, relative leadership 11/12.

Activity pressure 0.64; 4 reversal markers Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 28 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options55/100

JNJ shows bullish options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 2.2%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 2.2% Sentiment54/100

Weighted news tone is neutral across 36 relevant articles.

Argus Research Adjusts Johnson & Johnson Price Target to $300 From $290, Maintains Buy Rating Insiders13 / 7

13 acquisitions and 7 disposals in the latest 180-day insider tape.

 Earnings76d

Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.

 Research flow5 items

2 recent research articles and 3 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 2026263.4 USD4.1%234.8 USD169.9 USD0.6314.2539.4MOn
17 Jul 2026253.0 USD-1.5%232.8 USD169.3 USD0.639.7645.9MOn
10 Jul 2026257.0 USD-2.3%231.2 USD168.6 USD0.3010.3235.6MOn
3 Jul 2026263.0 USD3.3%229.6 USD167.9 USD0.1315.1231.6MOn
26 Jun 2026254.7 USD11.5%227.5 USD167.2 USD-0.2014.6454.9MOn
19 Jun 2026228.4 USD-5.2%225.8 USD166.5 USD-0.691.0443.0MOn
12 Jun 2026240.9 USD3.5%224.9 USD166.0 USD-0.797.9438.1MOn
5 Jun 2026232.8 USD3.3%223.3 USD165.4 USD-0.965.3435.5MOn
29 May 2026225.3 USD-3.3%221.7 USD164.9 USD-1.06-0.1933.6MOn
22 May 2026233.0 USD3.4%220.3 USD164.4 USD-1.054.9637.1MOn
15 May 2026225.4 USD2.4%218.8 USD163.8 USD-1.062.7941.5MOn
8 May 2026220.0 USD-2.6%217.6 USD163.3 USD-0.960.9234.6MOn
1 May 2026225.9 USD-0.1%216.5 USD162.8 USD-0.736.2537.2MOn
24 Apr 2026226.2 USD-2.9%215.2 USD162.3 USD-0.407.7041.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.